Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
The Memory and Aging Program at Butler Hospital is a world-wide leader in the fight against Alzheimer's. We are dedicated to developing breakthrough treatments for Alzheimer's disease through cutting-edge research into early detection and treatment.
Our research and future breakthroughs depend on the participation of people with normal memory who may be at risk for dementia and those who are already experiencing memory loss, as well as the support of committed community partners, supporters and volunteers.
Can healthy lifestyle changes help to protect memory and thinking in aging adults who are at risk? We’re looking for people ages 60 – 79 to participate in the U.S. POINTER study to find out.
READ MORE
After spending 25 years caring for Alzheimer’s patients Dr. Daniel Gibbs developed the disease himself. He’s now been living with it for at least 13 years, and he’s on a mission to spread an important message.
READ MORE